Clean Science Revenue, Profit Fall 20% in Q3; Zero Debt Maintained

CHEMICALS
Whalesbook Logo
AuthorVihaan Mehta|Published at:
Clean Science Revenue, Profit Fall 20% in Q3; Zero Debt Maintained
Overview

Clean Science & Technology reported a challenging Q3 FY2026, with standalone revenue down 20% YoY to ₹185 Cr and PAT declining 29.7% to ₹52 Cr due to margin compression. Despite the downturn, the company maintains its zero-debt status and continues significant capex for future growth.

📉 The Financial Deep Dive

Clean Science and Technology Limited (CSTL) has posted a challenging third quarter for FY2026, marked by a year-on-year contraction in both revenue and profitability.

The Numbers:

  • Q3 FY2026 Standalone Revenue: Reported at ₹185 Cr, a significant 20% decrease year-on-year from ₹231 Cr in Q3 FY2025.
  • Q3 FY2026 Consolidated Revenue: Stood at ₹219 Cr, down 9% YoY from ₹240 Cr.
  • Q3 FY2026 Standalone EBITDA: Declined by 29.4% YoY to ₹72 Cr.
  • Q3 FY2026 Standalone EBITDA Margin: Contracted to 40.3% from 44.8% in the prior year period, indicating pressure on operational profitability.
  • Q3 FY2026 Standalone Profit After Tax (PAT): Fell by 29.7% YoY to ₹52 Cr.
  • Q3 FY2026 Consolidated EBITDA: Was ₹72 Cr, a 26.5% decrease YoY.
  • Q3 FY2026 Consolidated PAT: Landed at ₹46 Cr, down 30.3% YoY.

For the nine-month period ending Q3 FY2026:

  • Standalone Revenue: Decreased by 8.7% YoY to ₹618 Cr.
  • Consolidated Revenue: Showed marginal growth of 0.6% to ₹707 Cr.
  • Both standalone and consolidated EBITDA and PAT for the nine-month period showed a decline of approximately 8-10% YoY.

The Quality:

The primary concern from the quarterly results is the margin compression, with standalone EBITDA margins shrinking by 450 basis points YoY. While the company did not detail free cash flow, it highlighted a significant capital expenditure of approximately ₹165 Cr during the first nine months of FY2026, primarily directed towards its subsidiary, Clean Fino Chem Ltd. (CFCL). A key positive is CSTL's reiteration of its 'Zero Debt Company' status, showcasing a robust balance sheet with no outstanding borrowings.

The Grill:

Crucially, the investor presentation does not include specific forward-looking financial guidance numbers or detailed commentary from a post-earnings conference call. This absence of concrete forward guidance leaves investors without a clear near-term outlook from management, making it difficult to ascertain expected recovery paths or growth trajectories.

🚩 Risks & Outlook:

The challenging business environment is cited as the primary reason for the current downturn. Key risks include the effective execution of the significant greenfield capex and the successful commercialization of new products amidst potentially subdued demand. The company's outlook is anchored on strategic initiatives: capitalizing on greenfield investments for new product launches (such as Hydroquinone and Catechol, which were commercialized in Q3), developing new chemical process technologies, focusing on high-value product segments, and expanding its market footprint both domestically (through import substitution) and internationally. The global shift towards sustainable chemistry is identified as a significant long-term opportunity.

The Board of Directors approved an interim dividend of ₹2 per share, signaling a commitment to shareholder returns even during a period of investment and market headwinds.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.